Targeted delivery of panitumumab-scaffold bosutinib-encapsulated polycaprolactone nanoparticles for EGFR overexpressed colorectal cancer- supplementary dataset

Aims: Panitumumab (anti-Erb)-conjugated polycaprolactone (PCL) nanoparticles loaded with bosutinib

(BTNB) were used to develop a targeted drug-delivery system for colon cancer cells. Materials & methods:

Using carbodiimide coupling, anti-Erb was conjugated to BTNB-loaded PCL nanoparticles. Dynamic light

scattering, scanning electron microscopy, transmission electron microscopy, Fourier-transform infrared

spectroscopy, differential scanning calorimetry, x-ray diffraction and thermogravimetric analysis were used

to analyze nanoparticles. Results: According to in vitro studies, anti-Erb-BTNB-PCL nanoparticles inhibited

HCT116 cells more than BTNB alone. Cell arrest at different phases was examined for apoptotic potential.

An in vivo efficacy study showed that anti-Erb-BTNB-PCL nanoparticles could target tumors selectively.

Conclusion: Anti-Erb-conjugated BTNB nanoparticles could specifically target colon cancer.